木瓜直播

木瓜直播's enterprise and investigative team covers a lot of ground. We jump in when there's breaking news in healthcare. We write second-day stories on the implications of that news. We craft compelling feature stories about interesting trends and people in medicine.

And then there are the special projects -- those deeper stories that take months to put together. Reporters immerse themselves in an issue, often to highlight wrongdoing or to bring clarity to controversy.

Yet these stories are the ones most often overlooked.

That's why 木瓜直播 is highlighting our strongest enterprise and investigative stories from this year. Our reporters published pieces for two high-profile fellowships in 2024: The journalism grant, and the data fellowship.

There were more investigations beyond that. Here are some of our most notable. We hope these offer some inspiration for the New Year.

NIHCM Fellowship: "Ozempic: Weighing the Risks and Benefits"

This wide-ranging series explored some of the key issues with novel glucagon-like peptide-1 (GLP-1) agonists for weight loss, including a deep dive into their potential cardiac benefits and what the data showed about weight regain after stopping the medication.

We also had a piece that detailed exactly how compounding pharmacies can make copies of these patented drugs, one that revealed steep increases in prescriptions for GLP-1 drugs in kids, and another that questioned whether pharmaceutical companies should be involved in telehealth platforms that offer these drugs.

Finally, we showed how some bariatric surgeons were being put out of work by these popular medications.

CHJ Data Fellowship: How Youth Gender-Affirming Care Bans Affected Care

For this project, 木瓜直播 analyzed prescription data, revealing that scripts for drugs used to delay the onset of puberty fell in 2023, the year most state bans went into effect. The piece explored how patients were figuring out alternate ways to get their care.

Our team also found out that New Mexico had become something of a haven for transgender youths, as many of its neighbors banned such care.

Other Investigations

Other 木瓜直播 investigations showed:

Conflict of interest disclosure policies at medical journals varied widely.

U.S. clinics promoted a questionable treatment -- "supportive oligonucleotide therapy" -- for everything from cancer and Lyme disease to bacterial and viral infections.

In 13 states, MDs and DOs still had separate licensing boards.

More states tried to cut training requirements for international medical graduates.

One doctor fought her insurance to get her baby's brain cancer treatment covered.

Comment